Literature DB >> 8792488

Epstein-Barr virus infection associated with interstitial nephritis and chronic fatigue.

A López-Navidad1, P Domingo, J C López-Talavera, N Rabella, G Verger.   

Abstract

Severe renal disease in the setting of Epstein-Barr virus (EBV) infection is exceedingly rare. We report here the case of a 22-year-old man with acute EBV infection associated with severe interstitial nephritis. The patient developed chronic fatigue and chronic renal failure with a serological profile typical of primary EBV infection. Clinical improvement with anti-EBNA seroconversion occurred after acyclovir therapy. Our patient illustrates that chronic fatigue with major organ dysfunction and a serological profile of primary infection can be seen in chronic EBV infection. In such a case, acyclovir may prove beneficial.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8792488     DOI: 10.3109/00365549609049073

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  4 in total

1.  Epstein-Barr virus infection of renal proximal tubule cells: possible role in chronic interstitial nephritis.

Authors:  J L Becker; F Miller; G J Nuovo; C Josepovitz; W H Schubach; E P Nord
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

2.  Combining an antiviral with rituximab in EBV-related haemophagocytic lymphohistiocytosis led to rapid viral clearance; and a comprehensive review.

Authors:  Christos Stefanou; Christiana Tzortzi; Fotini Georgiou; Chrystalla Timiliotou
Journal:  BMJ Case Rep       Date:  2016-12-09

Review 3.  Genetic, Epigenetic, and Environmental Factors Influencing Neurovisceral Integration of Cardiovascular Modulation: Focus on Multiple Sclerosis.

Authors:  Zohara Sternberg
Journal:  Neuromolecular Med       Date:  2015-10-26       Impact factor: 3.843

4.  Epstein-Barr virus-associated acute renal failure: diagnosis, treatment, and follow-up.

Authors:  Jeng-Daw Tsai; Hung-Chang Lee; Chun-Chen Lin; Der-Cherng Liang; Shu-Huey Chen; Fu-Yuan Huang
Journal:  Pediatr Nephrol       Date:  2003-05-15       Impact factor: 3.651

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.